Key fingerprint fragments of anti-hepatitis B virus agents using genetic function approximation method

LIU Hengping; WANG Jinzheng; GAO Chengzhe; XU Bin; LI Qingran; LIN Xinhao; LIN Kejiang

doi:10.11665/j.issn.1000-5048.20140404

Journal of China Pharmaceutical University > 2014 > 45(4): 405-409. > DOI: 10.11665/j.issn.1000-5048.20140404

LIU Hengping, WANG Jinzheng, GAO Chengzhe, XU Bin, LI Qingran, LIN Xinhao, LIN Kejiang. Key fingerprint fragments of anti-hepatitis B virus agents using genetic function approximation method[J]. Journal of China Pharmaceutical University, 2014, 45(4): 405-409. DOI: 10.11665/j.issn.1000-5048.20140404

Citation:

PDF (1992 KB)

Key fingerprint fragments of anti-hepatitis B virus agents using genetic function approximation method

More Information

Graphical Abstract

Abstract

Abstract

In this paper quantitative structure-activity relationships(QSAR)were developed on HBV DNA polymerase inhibitors to uncover the relationship between biological activity and the key structural features. The 2D QSAR model of fingerprint fragments was built using genetic function approximation(GFA)method with good internal(adjusted R-squared: 0. 911 9)and external prediction(r²_pred = 0. 848 9). The features of 8 fingerprint fragments obtained are consistent with 3D pharmacophore. These fingerprints are notably more effective than those based on a fragment dictionary or hashing library. The combination of these fingerprint fragments to novel molecule library provides an effective and efficient approach to virtual screening and de novo drug design.
- hepatitis B,
- fingerprint fragment,
- genetic function approximation method,
- 2D-QSAR

FullText(HTML)

References (19)

References

[1]	WHO. Hepatitis B[EB/OL]. 2013 [201307] http: //www.who.int/mediacentre/factsheets/fs204/en/.
[2]	Malik AH,Lee WM.Chronic hepatitis B virus infection:treatment strategies for the next millennium[J].Ann Intern Med,2000,132(9):723-731.
[3]	Zoulim F,Poynard T,Degos F,et al.A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine[J].J Viral Hepat,2006,13(4):278-288.
[4]	Yang HJ,Lee JH,Kim YJ,et al.Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance[J].J Med Virol,2012,84(3):424-430.
[5]	Litwin S,Toll E,Jilbert AR,et al.The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants:theoretical considerations[J].J Clin Virol,2005,34(Suppl 1):S96-S107.
[6]	Davis BJ, Erlanson DA. Learning from our mistakes: the ′unknown knowns′ in fragment screening[J].Bioorg Med Chem Lett,2013,23(10):2 844-2 852.
[7]	Tang YH,Lin KJ,You QD.Application of 2D molecular fingerprints based on molecular similarity in visual screening[J].J China Pharm Univ(中国药科大学学报),2009,40(2):178-184.
[8]	Chen L,Li YY,Zhao Q,et al.ADME evaluation in drug discovery.10.Predictions of P-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques[J].Mol Pharm,2011,8(3):889-900.
[9]	Myint KZ,Wang L,Tong Q,et al.Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions[J].Mol Pharm,2012,9(10):2 912-2 923.
[10]	Wikel JH,Dow ER.The use of neural networks for variable selection in QSAR[J].Bioorg Med Chem Lett,1993,3(4):645-651.
[11]	Leardi R,Boggia R,Terrile M.Genetic algorithms as a strategy for feature-selection[J].J Chemometrics,1992,6(5):267-281.
[12]	Friedman JH,Roosen CB.An introduction to multivariate adaptive regression splines[J].Stat Methods Med Res,1995,4(3):197-217.
[13]	Rogers D,Hopfinger AL.Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships[J].J Chem Inf Comput Sci,1994,34:854-866.
[14]	Fu X,Jiang S,Li C,et al.Design and synthesis of novel bis(L-amino acid)ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine(PMEA)with improved anti-HBV activity[J].Bioorg Med Chem Lett,2007,17(2):465-470.
[15]	Fu XZ,Ou Y,Pei JY,et al.Synthesis,anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir[J].Eur J Med Chem,2012,49:211-218.
[16]	Choi JR,Cho DG,Roh KY,et al.A novel class of phosphonate nucleosides.9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent[J].J Med Chem,2004,47:2 864-2 869.
[17]	Sekiya K,Takashima H,Udeda N,et al.2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl)esters as novel HBV-specific antiviral reagents[J].J Med Chem,2002,45(14):3 138-3 142.
[18]	Wang J,Singh US,Rawal RK,et al.Antiviral activity of novel 2′-fluoro-6′-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants[J].Bioorg Med Chem Lett,2011,21(21):6 328-6 331.
[19]	Zhang HW,Detorio M,Herman BD,et al.Synthesis,antiviral activity,cytotoxicity and cellular pharmacology of l-3′-azido-2′,3′-dideoxypurine nucleosides[J].Eur J Med Chem,2011,46(9):3 832-3 844.

Cited By

Get Citation

PDF

XML

Article views (1019) PDF downloads (2063)

Turn off MathJax

Article Contents

Abstract

References

Key fingerprint fragments of anti-hepatitis B virus agents using genetic function approximation method

Abstract

References

Catalog

Export File

Citation

Format

Content